MolecularMD Licenses IP from NYU, MSKCC

The company plans to use the BRAF-related IP in a PCR-based assay that could be used to help inform cancer treatment decisions.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.